Inflammatory Bowel Disease (IBD)

Intestinal Anatomy

To understand IBD, a review of gastrointestinal (GI) tract anatomy is helpful. This explanation is not complete, but it covers the basics.

The digestive system consists of a long tube (alimentary canal) that varies in shape and purpose as it winds its way through the body from the mouth to the anus (see diagram). The size and shape of the digestive tract varies according to the individual (e.g., age, sex, size, and disease state). The dimensions mentioned below are for an average adult male.

The upper part of the GI tract includes the mouth, throat (pharynx), esophagus, and stomach. When food enters the mouth, chewing mechanically breaks down and mixes food, while saliva begins to modify the food chemically, thus beginning the digestive process. Chewing and swallowing (ingesting) require conscious effort, but once food reaches the esophagus, an automatic, rhythmic motion (peristalsis) takes over, propelling the contents along. A number of body systems provide the chemicals necessary to complete digestion, absorption, and elimination. If all is going well, the passage of food from one area of the intestines to the next is precisely coordinated, so that food stays in each area for just the right amount of time.

Transit time is the duration between when food enters the mouth and when leftover waste finally passes out as stool (feces). A meal could take anywhere from 12-72 hours to travel through the digestive tract. Each person is unique; a normal bowel movement pattern for one person may be very different from those of family members or friends. Some individuals have an irregular pattern, never knowing what to expect. The composition and quantity of dietary intake, the presence of a GI disease or disorder, and other factors influence transit time.

Following the esophagus, and located within the left side of the abdominal cavity, is the stomach, a sac-like organ about 25 cm (~10”) long. It increases in diameter as it receives food, holding up to a maximum of about 4 litres (but do not eat so much as to extend the stomach fully). Strong chemicals bathe food to break it down into simpler forms, while the stomach’s thick walls keep these chemicals from entering the body as it squeezes its contents with strong circular and longitudinal muscles.

The lower part of the GI tract includes the small and large intestines. The names of these parts are a bit confusing, as the small intestine is about three times as long as the large intestine. Small and large refer to the diameter, which for the small intestine is about 2.5-3 cm (~1”) compared to 6.5-7 cm (~2.5”) for the large intestine.

The small intestine is a long and narrow coiled tube that extends from the stomach to the large intestine, winding around within the abdomen. It has an enormous internal surface area due to the presence of millions of tiny finger-like protrusions called villi, which are covered in hair-like protrusions called microvilli. This is where most digestion and absorption of food takes place. The first section of the small intestine, the duodenum, is the smallest segment, which is about the same length as the stomach (25 cm/~10”), followed by the jejunum (2.5 m/~8’) and the ileum (3.5 m/~11.5’), for a combined total of a little more than 6 m (~20’). Functions of the small intestine include secreting digestive enzymes and buffers, and absorbing nutrients. IBD patients should know that iron is absorbed in the duodenum and vitamin B12 and bile salts are absorbed in the last part of the ileum (terminal ileum).

The mucosa is the innermost layer of the GI tract wall; it is
responsible for both the secretion of digestive juices and the absorption of nutrients. The second layer is the submucosa, which consists of a dense layer of connective tissue with blood vessels, lymphatic vessels, and nerves. Outside of the submucosa is a layer of muscle, the muscularis externa. As these muscles contract, they propel food along the digestive tract. The outermost layer is the serosa, a thin layer of cells that secrete fluid, which reduces the friction caused by muscle movement.

The first part of the colon, the cecum, connects to the small intestine at the ileocecal valve, in the lower right area of the abdomen. The rest of the large bowel consists of the ascending colon (going upward on the right side of the abdomen), transverse colon (going leftward across the abdomen), and descending colon (going downward on the left side of the body), followed by the sigmoid colon. Altogether, the large intestine (colon) is about 1.25 m (~4′) long. The main function of the colon is to absorb water, form stool, and eliminate waste. The large intestine does not secrete digestive enzymes and does not have villi. The colon contains many varieties of friendly bacteria and yeasts to aid digestion and to prevent proliferation of harmful bacteria and yeasts. The colon ends in the rectum (about 15-20 cm/~6-8″ long), which briefly stores waste material until it is eliminated via the anus as stool, usually as a conscious choice.

Although not directly part of the digestive tract, the liver, gallbladder, and pancreas serve as accessory organs that are vital to the digestive process.

Inflammatory Bowel Disease

Since each individual is unique, issues discussed here will not apply to every person with IBD; however, we hope this information helps you understand this complex and chronic disease. Please be sure to discuss your particular circumstances with the health care professionals involved in your care.

Inflammatory bowel disease is a term that primarily refers to two diseases of the intestines: Crohn’s disease and ulcerative colitis. These diseases have a few similarities but do differ significantly in two key ways: the area of the digestive tract affected and the extent of the inflammation. More about other inflammatory bowel diseases later.

**Area Affected:** Ulcerative colitis only involves the colon and always begins at the anus, with the disease continuously progressing upward. In some cases, it can involve the entire large intestine. In ulcerative proctitis, a milder form of ulcerative colitis, inflammation reaches up from the anus no more than about 20 cm (~7-8″). In Crohn’s disease, the inflammation can be in multiple patches or one large patch, and may involve any area throughout the entire digestive tract, often affecting the last part of the small intestine (terminal ileum).

**Extent of Inflammation:** In ulcerative colitis, inflammation only involves the inner mucosa, while in Crohn’s disease, inflammation can extend right through the entire thickness of the bowel wall, from the mucosa, through the muscle, and can even include the thin outermost layer of digestive tract cells (serosa).

The inflammatory process causes dilation of blood vessels with increased warmth, oozing of fluid into the tissue, infiltration with inflammatory cells, and ulceration of the mucosa.

Inflammation can result from infectious agents such as bacteria, fungi, parasites, or even viruses. It can also arise from a chemical exposure, burn, trauma, or a number of other causes. The cause of IBD is undetermined but there is considerable research evidence to suggest that interactions between environmental factors, intestinal bacteria, immune dysregulation, and genetic predisposition are responsible. There is an increased risk for those who have a family member with the condition.

Although Crohn’s disease is currently the proper name for the condition, sometimes you might hear older terms, such as regional enteritis, terminal ileitis, granulomatous colitis, or ileocolitis used interchangeably.

A diagnosis of inflammatory bowel disease can occur at any point throughout life, with a high occurrence in youth and then again around 40-50 years of age. Approximately 0.7% of the Canadian population has IBD. Canada has among the highest prevalence and incidence yet reported in the world, at approximately 270,000 persons, with slightly more having Crohn’s disease than ulcerative colitis.

**Symptoms/Complications**

The most common symptom of IBD is diarrhea. Inflammation can affect transit time, usually causing food to pass more quickly and allowing less time for water
The patient requires a blood transfusion. Anemia may also arise from blood loss due to the ulcerations in the lining of the intestine. Surgery can increase the risk of fistulae. Abdominal Crohn’s disease may occur. When this connection is near the opening of the rectum, it is called an anal fistula. Fistulae also may occur in the rectum, it is called an anal fistula. Fistulae also may occur in other types of inflammatory bowel disease (IBD), particularly cramping. In Crohn’s disease, pressure can build up behind a narrowed portion (stricture) of the intestine and produce pain. Occasionally, the narrowing is so severe that a blockage of the intestine occurs, requiring immediate medication and, less frequently, surgical intervention.

Fever frequently accompanies inflammation of any type and is present in IBD.

IBD patients can experience tenesmus, which is the feeling of incomplete defecation, as well as a sudden, short, severe type of pain at the opening of the rectum.

Weight loss is common in Crohn's disease, due to the small intestine’s decreased ability to absorb sufficient nutrition. In children, a delay in growth and maturity might result. If possible, it is best to consult a pediatric gastroenterologist, who has specific training to manage the special needs of the growing child.

In Crohn’s disease, the rectum and anus can become a focal point for inflammation, with the formation of painful inflamed slits in the skin and superficial tissues, called anal fissures. Large pus pockets or abscesses may accumulate, producing severe pain and fever. An abnormal, tunnel-like connection between the intestine and the skin, called a fistula, may occur. When this connection is near the opening of the rectum, it is called an anal fistula. Fistulae also may occur in Crohn’s disease between loops of intestine within the abdomen or between the intestine and the abdominal wall. Abdominal surgery can increase the risk of fistulae.

Anemia, or low red blood cell count, commonly occurs from blood loss due to the ulcerations in the lining of the intestine. Occasionally, blood loss may be so severe that the patient requires a blood transfusion. Anemia may also be a consequence of general malnutrition due to nutrient malabsorption and the debilitating effects of IBD on a person’s body.

Other manifestations of inflammatory bowel disease include arthritis, skin problems, liver disease, kidney stones, and eye inflammation.

IBD patients who have ulcerative colitis or Crohn’s disease of the colon are at a slightly increased risk for colorectal cancer after having the disease for about 10-15 years, so screening for colorectal cancer should be at an earlier and more vigilant schedule in this group than for that of the general population.

**Diagnosis**

Malfunction of the intestinal tract may occur for a wide variety of reasons and some symptoms (diarrhea, pain, and weight loss) may be very similar to symptoms of other diseases or disorders. The accurate diagnosis of IBD is essential, and a physician will take steps to exclude other conditions.

A careful evaluation of the history of the illness is the first step toward a correct diagnosis. The physician will review factors such as when and how the symptoms began, what subsequent problems occurred, the nature of the diarrhea, the type of abdominal pain, as well as the characteristics and quantity of rectal bleeding.

In ulcerative colitis, the most useful diagnostic tool is the sigmoidoscope, a short instrument that allows visualization of the inside of the lower bowel. If necessary, during this procedure a physician can biopsy any suspected areas for further investigation. Viewing the lining of the colon with this instrument at regular intervals throughout the healing process allows a physician to monitor the disease. If needed, a longer, flexible instrument called a colonoscope can help the physician see farther up into the colon, sometimes as far as the terminal ileum (where the small and large intestine meet), which is a likely location for the formation of Crohn’s disease. In some cases, a gastroscope, entering the body via the mouth, is useful to confirm Crohn’s disease in the upper part of the GI tract.

Although less likely, a physician might request a barium X-ray. When needed for the upper GI area, the patient drinks a liquid that coats the walls of the esophagus and stomach. This drink contains barium, which shows up as bright white on X-rays, providing a contrasting picture of the shape and function of the upper GI tract. When needed to provide details of the lower GI tract, the patient undergoes a barium-containing enema to allow the physician to view the contours of the bowel. However, a colonoscopy offers a diagnostic advantage over a barium enema X-ray in that a physician can take biopsies during this procedure.

Other diagnostic tools include blood tests and examination of a stool sample for infectious agents and hidden (occult)
particularly pain and diarrhea, will improve quality of life for the patient. A number of treatments exist to address diarrhea and pain. Dietary adjustment may be beneficial and anti-diarrheal medications have a major role to play. Analgesics can be helpful for managing painful symptoms not controlled by other drugs listed below, which address the underlying inflammation. Acetaminophen (Tylenol®) is preferred over medications called non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil®, Motrin®), aspirin, and naproxen (Aleve®, Naprosyn®), as they can irritate the gut.

There are two types of anti-diarrheal medications directed at preventing cramps and controlling defecation. One group alters the muscle activity of the intestine, slowing down content transit. These include: nonnarcotic loperamide (Imodium®); narcotic agents diphenoxylate (Lomotil®), codeine, opium tinctorium and paregoric (camphor/opium); and anti-spasmodic agents hyoscymine sulfate (Levsin®), dicyclomine (Bentylol®), propantheline (Pro-Banthine®), and hyoscine butylbromide (Buscopan®).

The other group adjusts stool looseness and frequency by soaking up (binding to) water, regulating stool consistency so it is of a form and consistency that is easy to pass. These work in different ways; some include plant fibres, such as Benefibre®, Metamucil®, or Prodiem®, and cholestyramine resin (Questran®), which is a bile salt binder. Interestingly, plant fibres are also useful for constipation, due to their stool regulating effects.

If extra-intestinal signs of IBD occur, such as arthritis or inflamed eyes, the physician will address these conditions individually, as the patient may require referrals to other specialists. If anxiety and stress are major factors, a program of stress management may be valuable. (Ask for our pamphlet on Stress Management.)

Individuals with IBD may be anemic from a combination of factors, such as chronic blood loss or malabsorption of certain vitamins and minerals. Adding dietary supplements could help improve this condition. Heme iron (e.g., OptiFer® Alpha, Proferrin®) is quick acting and has a low side effect profile, so it is preferred over non-heme iron supplements. Occasionally, a blood transfusion may be necessary.

In Crohn’s disease, the most widely prescribed antibiotics are ciprofloxacin (Cipro®) and metronidazole (Flagyl®, Florazole ER®). Broad-spectrum antibiotics are important in treating secondary manifestations of the disease, such as peri-anal abscess and fistulae.
part of the gastrointestinal tract), followed by maintenance of remission (prevention of flare-ups).

To accomplish these goals, physicians aim treatment at controlling the ongoing inflammation in the intestinal tract, which will lead to improved symptoms. Treatments come in many forms, using various body systems to effect relief. A physician may prescribe any of the following medications alone or in combination. It could take some time to find the right mix for any specific patient, as each case of IBD is unique. Depending on the location of your disease, a combination of drug delivery methods (oral and rectal) could help to ensure that all areas of the disease are covered.

5-Aminosalicylic Acid (5-ASA)

The medication used to reduce inflammation in mild to moderate IBD with the longest record of success worldwide is 5-ASA, including mesalamine (Asacol®, Asacol 800®, Mesasal®, Mezavant®, Pentasa®, Salofalk®) and olsalazine sodium (Dipentum®), all available orally in the forms of tablets and capsules. 5-ASA medication is generally safe and well tolerated for long-term use. Depending on the location of your disease, you may be required to administer mesalamine (Pentasa®, Salofalk®) rectally, in the forms of enemas or suppositories. Patients typically use rectal medications nightly at first and, as the disease improves, treatments can become less frequent.

5-ASA helps to settle acute inflammation and, when taken on a long-term basis (maintenance), it tends to keep the inflammation inactive. It is important to keep up your medicine regimen even if your symptoms disappear and you feel well again. Maintenance therapy can be at the full initial dosage or at a reduced dosage and interval, depending on the disease response.

A combination of 5-ASA and sulfapyridine is available orally as sulfasalazine (Salazopyrin®).

Corticosteroids

To reduce inflammation for the shorter-term in IBD, corticosteroids might help. Oral medications include prednisone for mild to severe IBD and budesonide (Cortiment® for ulcerative colitis; Entocort® for Crohn’s disease) for mild to moderate disease, although prednisone tends to have greater side effects. Oral budesonide (Cortiment®, Entocort®) comes in two brands, which release medication at different points in the digestive tract. Hydrocortisone (Betnesol®, Cortenema®, Cortifoam®, Proctofoam®) is available in rectal formulations (enemas, foams, and suppositories).

Physicians can prescribe hydrocortisone (Solu-Cortef®) and methylprednisolone (Solu-Medrol®) for administration intravenously in-hospital. Corticosteroids should not be used for longer-term or maintenance therapy.

Immunosuppressive Agents

Physicians prescribe these drugs to prevent flare-ups of ulcerative colitis and Crohn’s disease, and to try to reduce dependence on steroids. They include azathioprine (Imuran®), cyclosporine, mercaptopurine/6-MP (Purinethol®), and methotrexate sodium. These medications can take up to twelve weeks of therapy to start working and six months to be fully effective. A newer medication, tofacitinib (Xeljanz®, is a Janus kinase (JAK) inhibitor, and it typically works faster than the other immunosuppressive medications. Xeljanz® is currently only available for individuals with ulcerative colitis.

Biologics

Biologic medications are important treatment options for those who have moderate to severe IBD. These products are specially developed antibodies, which selectively block molecules that are involved in the inflammatory process. Gastroenterologists routinely prescribe biologics, which include infliximab (Remicade®, adalimumab (Humira®), golimumab (Simponi®), vedolizumab (Entyvio®), ustekinumab (Stelara®), and most recently, two biosimilars of infliximab (Inflectra®, Remsima®), to control the symptoms (induce clinical remission) of inflammatory bowel diseases.

Crohn’s disease: Health Canada approved Remicade® in 2001 to induce clinical remission in Crohn’s disease, for ongoing use to maintain clinical remission, for reducing or eliminating corticosteroid use, for healing and closing fistulae, and for healing the lining of the bowel wall (mucosal healing). A biosimilar of infliximab (Inflectra®) was approved in 2016, and another biosimilar of infliximab (Remsima®) was approved in 2018. Humira®, a fully human monoclonal antibody, was approved in 2006 to induce clinical remission in Crohn’s disease and for ongoing use to maintain clinical remission. Subsequent biologics approved to treat Crohn’s disease are vedolizumab (Entyvio®), and ustekinumab (Stelara®).

Ulcerative colitis: Health Canada approved Remicade® in 2006 to induce and maintain clinical remission and mucosal healing, and for reducing or eliminating corticosteroid use. Health Canada approved a biosimilar of infliximab (Inflectra®) in 2016, and another biosimilar of infliximab (Remsima®) was approved in 2018. Simponi® was approved in 2013 to induce and maintain clinical remission and mucosal healing. Humira® was approved in 2013 for use to induce and maintain clinical remission. Entyvio®, a humanized, anti-a4b7 integrin monoclonal antibody was approved in 2015 for the treatment of adult patients with moderate to severe ulcerative colitis who have had an inadequate response, loss of response to, or were intolerant to, either conventional therapy or infliximab.
An emerging surgical therapy is intestinal transplantation, but there are barriers yet to overcome, such as tissue rejection and inflammation in the newly transplanted organ.

**What is a Flare?**

When you have inflammatory bowel disease, your physician will try to find the right medications to control your symptoms. However, since there is no cure, the systemic disease is always there. When the symptoms aren't present, you are in remission. If the symptoms return, especially if they are worse than before, it is a flare. This is why it is important to continue taking any medications your doctor prescribes to treat your IBD, even if you feel better. If you stop taking your medication, then you can increase your chance of experiencing a flare and progression of the disease. Infections, stress, and taking antibiotics or NSAIDs (including aspirin and ibuprofen) can also make you more susceptible to a flare.

**When to Get Treatment**

An increase in inflammation causes a flare, and the nature of inflammation means that you should treat it as quickly as you can. Inflammation grows exponentially, because inflammation itself causes an increase in inflammation. The longer you leave it untreated, the worse it will get. In addition, untreated inflammation not only leads to the symptoms associated with IBD, it can also increase your risk of developing complications such as colorectal cancer down the line. Pay attention to your symptoms, and visit your physician if you notice that they change or increase even a small amount.

**Flare Treatment Options**

Particularly if you are seeing a gastroenterologist who has a long waiting time to get an appointment, it is important to discuss with your physician in advance exactly what he or she would like you to do if the disease flares. You might be taking medication regularly but still experience a flare. Typically, your physician will provide a prescription for a rectal preparation that you could purchase and use immediately, to avoid going untreated while waiting to get into the office. However, your physician might still want you to call the office to report your symptoms. This is an important conversation to have with your health care team, so you can prepare for some self-management when necessary, while keeping them aware of your condition.

When you are having disease symptoms, the first step is usually to increase (step up) your current treatment. Ask your doctor to explain your options as to what you should do between visits:
- increase the dose of your oral medication (tablets)
- use a rectal formulation (suppository or enema)
- a combination of the above
Your specific situation and history will determine what your physician recommends. Ideally, you should have a plan in place outlining what you can do if you have a flare. However, if you have severe symptoms you should seek immediate help, even if that means heading to the hospital emergency room.

**Oral vs Rectal Treatments**

Most physicians prescribe IBD patients oral versions of 5-ASAs or corticosteroids, since this is a patient-preferred delivery method of medication. However, even though they have specially designed release mechanism, they might not reach and treat the area where the disease is most active.

For example, when you apply sunscreen to your skin, you need to make sure that you cover every exposed part to protect it from the sun. When applying these treatments to your rectum and lower colon, you need to make sure that the product covers all of the inflamed areas.

Oral tablets might not be the optimal way to reach the end of the colon, where stool and the fact that ulcerative colitis patients have diarrhea, might interfere with its effectiveness. Unfortunately, this is also the area in the colon where a flare usually starts. The best way to reach this particular area is by inserting the drug directly into the rectum.

A suppository will travel upward and usually reach about 15 cm inside from the anus. An enema (liquid form) will reach farther, about 60 cm. Patients usually insert these formulations before bedtime, and this way the medication is retained as long as possible. Stool does not typically interfere with the drug, since a patient administers these medications right before bed when the bowel area is typically relatively empty.

Rectal preparations are particularly good at treating urgency and bleeding, symptoms that often are very bothersome to patients. A positive response often occurs within days of treatment.

**Administering Rectal Therapies**

To get the best coverage of topical rectal therapies, it is best to lie down on your left side. As you will see from the accompanying diagrams, the human anatomy is not symmetrical and the way the organs lay when on the left side makes for better medication administration.

**Is it important to treat a flare early, or is it ok to wait a bit?**

Inflammation typically does not resolve without treatment and early intervention has a better outcome than waiting to treat. At an early stage of a flare, a more optimal treatment with your baseline (5-ASA) treatment is often enough to get the inflammation under control. If you wait, there is a greater risk that you might need drugs with greater side effects, such as oral steroids. By waiting, you will have to manage longer with your symptoms before getting relief. Living with constant or longer periods of inflammation might increase your risk for future complications, as inflammation might cause damage to the gut wall that accumulates in severity with each flare.

If you are experiencing a worsening of your symptoms, you have probably already had the flare for some time without symptoms. Evidence shows that a stool test for inflammation in the colon, called fecal calprotectin, is often elevated for two to three months before any symptoms appear. Your colon might also start to show visual (during colonoscopy) evidence of inflammation before you have symptoms, or at least indicate an increased risk for a flare.

Looking into the colon gives a better, more reliable picture of what is truly going on with your disease. For this reason, your specialist might suggest a colonoscopy so he or she can have a closer look inside your colon to determine the best course of action. However, in most instances, a physician might still base a decision to prescribe medication on the severity and the nature of your symptoms. This is particularly the case when the symptoms are still mild.

**Other Types of IBD**

While most cases of IBD are either Crohn’s disease or ulcerative colitis, these aren’t the only types of IBD. The following are rare types of IBD, some of which it is possible to recover from completely.

**Ischemic Colitis**

The word ‘ischemia’ refers to an inadequate blood flow to a certain part of the body. This lack of blood supply means that not enough oxygen, glucose, and other materials are able...
to reach the cells to keep them alive and functioning. Ischemic colitis is the disease that occurs when reduced blood flow to the digestive tract causes inflammation and injury, which leads to IBD symptoms. Ischemic colitis typically occurs in the left area of the abdomen, where it causes considerable pain.

The reduced blood flow can come from a problem with the body’s circulation, such as low blood pressure, or localized events that cause reduced blood flow around the intestinal tract, including blood clots and narrowed or blocked blood vessels. However, there is often no identifiable cause.

Treatment often involves intravenous nutrition in order to allow the bowel to rest, which typically resolves the disease within one or two weeks. However, in some cases, surgery might be necessary.

**Diversion Colitis**

There are many reasons that a person might require an ileostomy or a colostomy, and these include intestinal obstruction, bowel injury, infection in the bowel, and colorectal cancer. Some individuals with ulcerative colitis or Crohn’s disease require an ostomy after having damaged tissue removed. There are many risks to this type of surgery, one of which is diversion colitis. Diversion colitis often disappears after full healing from the ostomy surgery, but sometimes further anti-inflammatory treatment is necessary.

**Radiation Enteritis**

This disease occurs as a complication from radiation therapy, in which radiation of the abdominal area causes irritation and inflammation to the intestine. Physicians take precautions to avoid radiation exposure to the intestine, but sometimes damage does occur. Many individuals undergoing radiation develop acute radiation enteritis, which is temporary, but some patients develop chronic radiation enteritis, which can last for months or years after radiation treatment. Symptoms include diarrhea, abdominal pain and cramping, rectal bleeding, and nausea. Treatment involves dietary changes to increase nutrient intake and to allow the bowel to heal, and taking medications to treat diarrhea, pain, and inflammation. If symptoms are severe, it might be necessary for the patient to cease radiation therapy, and possibly undergo surgery is sometimes necessary.

**Microscopic Colitis (Lymphocytic Colitis & Collagenous Colitis)**

There are two types of microscopic colitis, so called because the inflammation is too small to detect during colonoscopy, and requires microscope analysis of a tissue sample (biopsy). It is common for physicians to mistake symptoms of microscopic colitis for other conditions, such as irritable bowel syndrome, gastroenteritis, and celiac disease. Microscopic colitis includes collagenous colitis and lymphocytic colitis. The most common symptoms include abdominal pain and watery diarrhea that is not bloody. Researchers believe that in some cases, non-steroidal anti-inflammatory drugs (NSAIDs) can cause this disease, because ceasing to take these medications can result in symptom resolution.

We still don’t know much about the development, progression, and treatment of these diseases. The key differentiation between collagenous colitis and lymphocytic colitis is that collagenous colitis involves thickening of the sub-epithelial collagen table. Lymphocytic colitis affects females and males equally, but collagenous colitis is more common in women, with approximately 90% of cases affecting females, typically between 50-70 years of age.

Treatment can involve cessation of NSAIDs if the physician believes it could be the cause, and in some cases taking medications, such as 5-ASA, might be necessary.

**Outlook**

The future lies in education and research. Education of both the public and the medical profession is required to emphasize the importance of inflammatory bowel disease research. Many of the following areas need further investigation:

- the chemistry of the normal, as well as diseased intestine,
- further study of tissue changes that occur in inflammation,
- genetic factors,
- the role of nutrition,
- gut bacteria,
- the relative incidence of the diseases, as determined by accurate population surveys,
- emotional and psychiatric implications,
- the role of infectious agents,
- the study of the nature of inflammatory response, and
- clinical trials of new forms of therapy.

A partnership between physicians and researchers interested in the study of these diseases, along with patients, their families, and their friends, is the best hope toward finding the cause or causes, and the cure, of inflammatory bowel disease. Please support the GI Society’s educational and research initiatives.

Visit www.badgut.org for frequently asked questions about inflammatory bowel disease. If you do not have internet access, we would be happy to send them to you by mail. Just phone (toll free) 1-866-600-4875.
NOTES:

---

ABOUT US

As the Canadian leader in providing trusted, evidence-based information on all areas of the gastrointestinal (GI) tract, the Gastrointestinal Society is committed to improving the lives of people with GI and liver conditions, supporting research, advocating for appropriate patient access to health care, and promoting gastrointestinal and liver health.

The Inside Tract®, our quarterly newsletter, provides the latest news on digestive and liver research, disease and disorder treatments (e.g., medications, nutrition), and a whole lot more. If you have any kind of digestive problem, then you will want this timely, informative publication.

Please subscribe today!

The GI Society, in partnership with the Canadian Society of Intestinal Research, produced this pamphlet under the guidance of affiliated health care professionals. This document is not intended to replace the knowledge, diagnosis, or care of your physician. © GI Society 2019. All rights reserved.

SUBSCRIPTION/DONATION FORM

Purchase Information
☐ I enclose a donation of $_________/Eligible for a tax receipt
☐ I enclose a $20 annual subscription fee ($30 outside Canada)
Total $_________

Name (Mr./Mrs./Ms./Dr./Other ________) Please circle one

Company Name (Optional)

Street Address

City, Province, Postal Code

Daytime Phone Email

☐ Patient  ☐ Friend/Family Member  ☐ Professional

Diagnosis/Area of Interest (This optional information helps us to determine which topics might be of interest to you and is kept strictly confidential. We never sell our lists.)

Would you like more information? Please list your topics.

Payment:  ☐ Visa  ☐ Mastercard  ☐ Cheque Enclosed*

Credit Card Number Expiry Date

*Make cheque payable to the GI Society.

Gastrointestinal Society
231-3665 Kingsway
Vancouver, BC V5R 5W2
Phone: 604-873-4876

Toll-free: 1-866-600-4875 Fax: 1-855-875-4429 Email: info@badgut.org Website: www.badgut.org

Charitable Registration Number: 817065362RR0001